Stocks Under $10: Why Sprint is a Strong Buy

Richard Suttmeier  |

Sprint Nextel (S) – ($7.15) has been upgraded to a Strong Buy rating according to ValuEngine with fair value at $7.61, which makes the stock 6.0% undervalued. The one-year price target is $8.18. ValuEngine Profile – “Sprint Nextel offers a comprehensive range of wireless and wireline communications services to consumer, business and government customers. Sprint Nextel is widely recognized for developing, engineering and deploying innovative technologies, including two robust wireless networks offering industry leading mobile data services; instant national and international push-to-talk capabilities; and an award-winning and global Tier 1 Internet backbone.”

Analysis – The daily chart for Sprint shows declining momentum with the stock above its 21-day, 50-day and 200-day simple moving averages at $6.92, $6.36 and $5.60. My semiannual value level is $6.90 with a monthly pivot at $7.20 and weekly risky level at $7.28.


Courtesy of Thomson / Reuters

Ticker

Company Name

Mkt Price

Fair Value

One-Year Price Target

Last 12-Mon Retn (%)

5-Yr Avg Retn (%)

P/E Ratio

S

SPRINT NEXTEL

7.15

7.61

8.18

188.31

-5.53

n/a

If you have any questions, please contact me at Rsuttmeier@gmail.com.  

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
S Sprint Corporation 5.97 -0.10 -1.65 11,548,261 Trade
DUK Duke Energy Corporation (Holding Company) 90.75 -0.15 -0.17 3,651,850 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.